Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.52 +2.35%

+$0.09 today

Market cap
$94.59M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.99M

Average 0.54M

Returns on capital

Voyager Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-61.1%

avg -44.6%

ROIC

-56.4%

avg -26.4%

ROA

-47.5%

avg -19.3%

Analysis

ROA is currently the strongest return metric at -47.5% versus its period average of -19.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Alfred W. Sandrock Jr.

CEO & DirectorUSD 1.05M68——

Robin Swartz

PresidentUSD 738.95K56267.99K0.44%

Krystof Bankiewicz

Founder————

Mathieu Nonnenmacher

Vice President of Gene Therapy————

Mihalis Kariolis

Vice President of Non-Viral Therapeutics————

Todd Carter

Chief Scientific Officer—56——

Amy Quinlan

Principal Accounting Officer—5128.50K0.05%

Trista Morrison

Chief Corporate Affairs Officer & Chief of Staff to the Chief Executive Officer—49——

Mark A. Kay

Founder—68——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

11

$297,956.76

Net Transaction Value

−$297,956.76

Net selling

Most Active

Sandrock Alfred

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 2, 26

Sandrock Alfred

Direct

Sell$44.5K
Feb 24, 26

Swartz Robin

Direct

Sell$24.3K
Feb 24, 26

Sandrock Alfred

Direct

Sell$53.8K
Feb 24, 26

Jorgensen Nathan D.

Direct

Sell$17.6K
Feb 24, 26

Carter Todd Alfred

Direct

Sell$15.7K
Feb 18, 26

Swartz Robin

Direct

Sell$13.4K
Feb 18, 26

Carter Todd Alfred

Direct

Sell$11.4K
Feb 18, 26

Sandrock Alfred

Direct

Sell$40K
Feb 10, 26

Swartz Robin

Direct

Sell$17.6K
Feb 10, 26

Sandrock Alfred

Direct

Sell$46.1K

1–10 of 11

Summary

Insiders reported 0 buys worth $0.00 and 11 sells worth $297,956.76 over the last 12 months. That adds up to net selling of $297,956.76. Sandrock Alfred was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A-0.4%
+15.1% (5yr)4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Recent growth has been strongest in Revenue at -0.4% over three years. Forward estimates point to Revenue at +15.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Voyager Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about VYGR's management, answered from reported figures.

Who manages VYGR?

Voyager Therapeutics, Inc. (VYGR) lists 9 active executives. The top listed executive is Alfred W. Sandrock Jr., CEO & Director.

Are VYGR insiders buying or selling?

Recent insider activity shows net buying of $53.52M.